CN112543639A - 用于递送mrna和长核酸的脂质纳米颗粒组合物 - Google Patents

用于递送mrna和长核酸的脂质纳米颗粒组合物 Download PDF

Info

Publication number
CN112543639A
CN112543639A CN201980050099.7A CN201980050099A CN112543639A CN 112543639 A CN112543639 A CN 112543639A CN 201980050099 A CN201980050099 A CN 201980050099A CN 112543639 A CN112543639 A CN 112543639A
Authority
CN
China
Prior art keywords
composition
group
groups
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050099.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·西格沃特
程强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CN112543639A publication Critical patent/CN112543639A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980050099.7A 2018-06-19 2019-06-19 用于递送mrna和长核酸的脂质纳米颗粒组合物 Pending CN112543639A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687010P 2018-06-19 2018-06-19
US62/687010 2018-06-19
PCT/US2019/037904 WO2019246203A1 (en) 2018-06-19 2019-06-19 Lipid nanoparticle compositions for delivery of mrna and long nucleic acids

Publications (1)

Publication Number Publication Date
CN112543639A true CN112543639A (zh) 2021-03-23

Family

ID=68983272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050099.7A Pending CN112543639A (zh) 2018-06-19 2019-06-19 用于递送mrna和长核酸的脂质纳米颗粒组合物

Country Status (8)

Country Link
US (1) US20210121411A1 (cg-RX-API-DMAC7.html)
EP (1) EP3810148A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021528426A (cg-RX-API-DMAC7.html)
CN (1) CN112543639A (cg-RX-API-DMAC7.html)
AU (2) AU2019288373B2 (cg-RX-API-DMAC7.html)
CA (1) CA3103528A1 (cg-RX-API-DMAC7.html)
GB (2) GB2596224B (cg-RX-API-DMAC7.html)
WO (1) WO2019246203A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637708A (zh) * 2021-08-09 2021-11-12 中国科学院过程工程研究所 一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
CN116271105A (zh) * 2023-05-18 2023-06-23 上海贝斯昂科生物科技有限公司 一种适于rpe细胞转染的脂质纳米颗粒及其应用
CN117177954A (zh) * 2021-04-13 2023-12-05 成都威斯津生物医药科技有限公司 用于核酸递送的可离子化脂质及其组合物
WO2024138370A1 (zh) * 2022-12-27 2024-07-04 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
WO2024183821A1 (zh) * 2023-03-09 2024-09-12 上海吉量医药工程有限公司 可离子化脂质分子及其制备方法和应用

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102764250B1 (ko) 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
KR102712142B1 (ko) 2017-07-31 2024-10-07 리제너론 파마슈티칼스 인코포레이티드 Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2606038B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
KR20220024053A (ko) 2019-06-14 2022-03-03 리제너론 파마슈티칼스 인코포레이티드 타우병증의 모델
KR20220044816A (ko) * 2019-08-12 2022-04-11 인티그레이티드 나노테라퓨틱스 아이엔씨. 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
CN111467321A (zh) * 2020-03-26 2020-07-31 深圳市新合生物医疗科技有限公司 一种mRNA核酸类药物胞内递送系统、制备方法和应用
US20240293317A1 (en) * 2020-04-20 2024-09-05 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof
GB202008821D0 (en) * 2020-06-10 2020-07-22 Highersteaks Ltd Systems and methods for cell conversion
MX2023000511A (es) * 2020-07-10 2023-02-13 Genevant Sciences Gmbh Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
MX2023011243A (es) 2021-03-23 2023-12-14 Recode Therapeutics Inc Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
WO2022212838A1 (en) * 2021-04-02 2022-10-06 Tiba Biotech Llc Dendritic architectures as nonviral vectors in gene delivery
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
US20260151350A1 (en) * 2021-12-27 2026-06-04 The Board Of Regents Of The University Of Texas System Compositions and methods for targeted delivery to cells
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
WO2024086929A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc. Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
WO2024112775A1 (en) * 2022-11-25 2024-05-30 Beam Therapeutics Inc. Compositions and methods for editing a transthyretin gene
IL321026A (en) 2022-12-08 2025-07-01 Recode Therapeutics Inc Nanoparticle formulations and their uses
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025091377A1 (en) * 2023-11-02 2025-05-08 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026122685A1 (en) 2024-12-03 2026-06-11 Orna Therapeutics, Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026165530A1 (en) 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20170121279A1 (en) * 2015-09-14 2017-05-04 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
US20170240501A1 (en) * 2012-03-29 2017-08-24 Shire Human Genetic Therapies, Inc. Ionizable cationic lipids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2760706C (en) * 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20170240501A1 (en) * 2012-03-29 2017-08-24 Shire Human Genetic Therapies, Inc. Ionizable cationic lipids
US20170121279A1 (en) * 2015-09-14 2017-05-04 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONG ET AL.: "Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates", PROC. NATL. ACAD. SCI. USA, vol. 111, no. 11, pages 3955 - 3960, XP055167076, DOI: 10.1073/pnas.1322937111 *
MILLER ET AL.: "Non-viral CRISPR/Cas gene editing in vitro and in viva enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA", ANGEWANDTE CHEMIE, vol. 56, no. 4, pages 1059 - 1063 *
ZHOU ET AL.: "Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model", PROC. NATL. ACAD. SCI. USA, vol. 113, no. 3, pages 520 - 525, XP055897032, DOI: 10.1073/pnas.1520756113 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117177954A (zh) * 2021-04-13 2023-12-05 成都威斯津生物医药科技有限公司 用于核酸递送的可离子化脂质及其组合物
CN117177954B (zh) * 2021-04-13 2024-06-04 成都威斯津生物医药科技有限公司 用于核酸递送的可离子化脂质及其组合物
CN113637708A (zh) * 2021-08-09 2021-11-12 中国科学院过程工程研究所 一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
WO2024138370A1 (zh) * 2022-12-27 2024-07-04 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
WO2024183821A1 (zh) * 2023-03-09 2024-09-12 上海吉量医药工程有限公司 可离子化脂质分子及其制备方法和应用
CN116271105A (zh) * 2023-05-18 2023-06-23 上海贝斯昂科生物科技有限公司 一种适于rpe细胞转染的脂质纳米颗粒及其应用
CN116271105B (zh) * 2023-05-18 2023-08-25 上海贝斯昂科生物科技有限公司 一种适于rpe细胞转染的脂质纳米颗粒及其应用

Also Published As

Publication number Publication date
AU2019288373B2 (en) 2025-05-29
GB2596224A (en) 2021-12-22
GB202100678D0 (en) 2021-03-03
AU2025220887A1 (en) 2025-09-18
GB2589795A (en) 2021-06-09
US20210121411A1 (en) 2021-04-29
GB2589795B (en) 2022-09-07
GB2596224B (en) 2022-09-07
EP3810148A1 (en) 2021-04-28
AU2019288373A1 (en) 2021-01-14
WO2019246203A1 (en) 2019-12-26
EP3810148A4 (en) 2022-06-08
GB202107391D0 (en) 2021-07-07
JP2021528426A (ja) 2021-10-21
JP2024150688A (ja) 2024-10-23
CA3103528A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JP7815196B2 (ja) 核酸を臓器特異的送達するための組成物および方法
AU2019288373B2 (en) Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
JP2025108518A (ja) 核酸を臓器特異的送達するための組成物および方法
CN108271360B (zh) 亲脂阳离子树枝状聚合物及其用途
US12357580B2 (en) Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
JP2024516164A (ja) 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子
HK40042190A (en) Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
HK40055120A (en) Compositions and methods for organ specific delivery of nucleic acids
HK40055120B (en) Compositions and methods for organ specific delivery of nucleic acids
HK40055907A (en) Compositions and methods for organ specific delivery of nucleic acids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042190

Country of ref document: HK